Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
Cancer Research
|
September 19, 2012
CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy
Joseph M Tuscano, Jason Kato, David Pearson, et al.
British Journal of Haematology
|
March 11, 2014
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
Joseph M Tuscano, Mrinal Dutia, Karen Chee, et al.
Molecular Pharmaceutics
|
April 26, 2012
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma
Jason Kato, Yuanpei Li, Kai Xiao, et al.
Molecular Imaging and Biology
|
October 25, 2008
Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts
Shiloh M Martin, Robert T O'Donnell, David L Kukis, et al.
PET Clinics
|
July 5, 2024
Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities
Clemens Mingels, Hande Nalbant, Hasan Sari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2021
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Joseph M Tuscano, Christina Poh, Paul Kaesberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 3, 2021
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center
Matthew E Tenold, Benjamin N Moskoff, Rajeev Krishnan, et al.
Frontiers in Oncology
|
March 29, 2021
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Matthew E Tenold, Benjamin N Moskoff, David J Benjamin, et al.
Blood
|
January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Joseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Cancers
|
May 1, 2019
A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth
Christoph F A Vogel, Yasuhiro Ishihara, Claire E Campbell, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
Cancer Research
|
September 19, 2012
CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy
Joseph M Tuscano, Jason Kato, David Pearson, et al.
British Journal of Haematology
|
March 11, 2014
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
Joseph M Tuscano, Mrinal Dutia, Karen Chee, et al.
Molecular Pharmaceutics
|
April 26, 2012
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma
Jason Kato, Yuanpei Li, Kai Xiao, et al.
Molecular Imaging and Biology
|
October 25, 2008
Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts
Shiloh M Martin, Robert T O'Donnell, David L Kukis, et al.
PET Clinics
|
July 5, 2024
Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities
Clemens Mingels, Hande Nalbant, Hasan Sari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2021
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Joseph M Tuscano, Christina Poh, Paul Kaesberg, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 3, 2021
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center
Matthew E Tenold, Benjamin N Moskoff, Rajeev Krishnan, et al.
Frontiers in Oncology
|
March 29, 2021
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Matthew E Tenold, Benjamin N Moskoff, David J Benjamin, et al.
Blood
|
January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Joseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Cancers
|
May 1, 2019
A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth
Christoph F A Vogel, Yasuhiro Ishihara, Claire E Campbell, et al.
Page
of 7